BridgeMD
Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis: Randomised Prospective Study.
EU CTIS ID: 2024-519126-20-00
What this study is testing
To assess the impact of the administration of a long-acting GnRH agonist prior to frozen embryo transfer (FET) on clinical pregnancy rates within an assisted reproductive technology (ART) protocol, in patients with endometriosis and/or adenomyosis.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Women aged 18 to 36 with endometriosis and/or adenomyosis
- Having undergone IVF/ICSI with freeze-all, and for whom a blastocyst FET is planned
- A normal uterine cavity
- An MRI with contrast injection confirming endometriosis and/or adenomyosis during the inclusion visit (MRI performed after patient selection if no results from the past 6 months are available or interpretable)
- Having signed a consent form
- Affiliated with a health insurance plan
You likely can't join if
- BMI > 35
- Pregnancy and breast
- History of implantation failures (≥2)
- Endometrial abnormalities
- Known uni or bilateral hydrosalpinx
- Known hypersensitivity to GnRH, GnRH analogues, or any excipients in DECAPEPTYL® LP, 11.25 mg
See the full eligibility criteria
- Women aged 18 to 36 with endometriosis and/or adenomyosis
- Having undergone IVF/ICSI with freeze-all, and for whom a blastocyst FET is planned
- A normal uterine cavity
- An MRI with contrast injection confirming endometriosis and/or adenomyosis during the inclusion visit (MRI performed after patient selection if no results from the past 6 months are available or interpretable)
- Having signed a consent form
- Affiliated with a health insurance plan
- BMI > 35
- Pregnancy and breast
- History of implantation failures (≥2)
- Endometrial abnormalities
- Known uni or bilateral hydrosalpinx
- Known hypersensitivity to GnRH, GnRH analogues, or any excipients in DECAPEPTYL® LP, 11.25 mg
- Known hypersensitivity to estradiol/progesterone/acetylsalicylic acid/folic acid/cefixime/levofloxacin
- Known or suspected breast cancer, or history of breast cancer
- Known or suspected cancer of the reproductive system, or history of reproductive system cancer
- Known or suspected estrogen-dependent malignant tumors
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.